BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 31534554)

  • 1. ATF4 destabilizes RET through nonclassical GRP78 inhibition to enhance chemosensitivity to bortezomib in human osteosarcoma.
    Luo J; Xia Y; Yin Y; Luo J; Liu M; Zhang H; Zhang C; Zhao Y; Yang L; Kong L
    Theranostics; 2019; 9(21):6334-6353. PubMed ID: 31534554
    [No Abstract]   [Full Text] [Related]  

  • 2. GRP78 inhibition enhances ATF4-induced cell death by the deubiquitination and stabilization of CHOP in human osteosarcoma.
    Luo J; Xia Y; Luo J; Li J; Zhang C; Zhang H; Ma T; Yang L; Kong L
    Cancer Lett; 2017 Dec; 410():112-123. PubMed ID: 28947141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer.
    Bagheri-Yarmand R; Williams MD; Grubbs EG; Gagel RF
    J Clin Endocrinol Metab; 2017 Mar; 102(3):933-941. PubMed ID: 27935748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kuanoniamine C stimulates bortezomib-induced cell death via suppression of glucose-regulated protein 78 in osteosarcoma.
    Machihara K; Namba T
    Biochem Biophys Res Commun; 2020 Jun; 527(1):289-296. PubMed ID: 32446382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib sensitizes human osteosarcoma cells to adriamycin-induced apoptosis through ROS-dependent activation of p-eIF2α/ATF4/CHOP axis.
    Xian M; Cao H; Cao J; Shao X; Zhu D; Zhang N; Huang P; Li W; Yang B; Ying M; He Q
    Int J Cancer; 2017 Sep; 141(5):1029-1041. PubMed ID: 28524233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel dual kinase function of the RET proto-oncogene negatively regulates activating transcription factor 4-mediated apoptosis.
    Bagheri-Yarmand R; Sinha KM; Gururaj AE; Ahmed Z; Rizvi YQ; Huang SC; Ladbury JE; Bogler O; Williams MD; Cote GJ; Gagel RF
    J Biol Chem; 2015 May; 290(18):11749-61. PubMed ID: 25795775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crosstalk between ATF4 and MTA1/HDAC1 promotes osteosarcoma progression.
    Zeng H; Zhang JM; Du Y; Wang J; Ren Y; Li M; Li H; Cai Z; Chu Q; Yang C
    Oncotarget; 2016 Feb; 7(6):7329-42. PubMed ID: 26797758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CK1δ stimulates ubiquitination-dependent proteasomal degradation of ATF4 to promote chemoresistance in gastric Cancer.
    Feng L; Li M; Hu X; Li Y; Zhu L; Chen M; Wei Q; Xu W; Zhou Q; Wang W; Chen D; Wang X; Jin H
    Clin Transl Med; 2021 Oct; 11(10):e587. PubMed ID: 34709767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced antitumor effect of combination of annexin A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo.
    Jia C; Kong D; Guo Y; Li L; Quan L
    Biochem Biophys Res Commun; 2018 Nov; 505(3):720-725. PubMed ID: 30292410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.
    Roué G; Pérez-Galán P; Mozos A; López-Guerra M; Xargay-Torrent S; Rosich L; Saborit-Villarroya I; Normant E; Campo E; Colomer D
    Blood; 2011 Jan; 117(4):1270-9. PubMed ID: 21106982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining GRP78 suppression and MK2206-induced Akt inhibition decreases doxorubicin-induced P-glycoprotein expression and mitigates chemoresistance in human osteosarcoma.
    Xia YZ; Yang L; Xue GM; Zhang C; Guo C; Yang YW; Li SS; Zhang LY; Guo QL; Kong LY
    Oncotarget; 2016 Aug; 7(35):56371-56382. PubMed ID: 27486760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
    Kim A; Seong KM; Kang HJ; Park S; Lee SS
    Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma.
    Abdel Malek MA; Jagannathan S; Malek E; Sayed DM; Elgammal SA; Abd El-Azeem HG; Thabet NM; Driscoll JJ
    Oncotarget; 2015 Feb; 6(5):3098-110. PubMed ID: 25605012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CircRNA ITCH increases bortezomib sensitivity through regulating the miR-615-3p/PRKCD axis in multiple myeloma.
    Liu J; Du F; Chen C; Li D; Chen Y; Xiao X; Hou X
    Life Sci; 2020 Dec; 262():118506. PubMed ID: 33031827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
    Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
    J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose deprivation induces chemoresistance in colorectal cancer cells by increasing ATF4 expression.
    Hu YL; Yin Y; Liu HY; Feng YY; Bian ZH; Zhou LY; Zhang JW; Fei BJ; Wang YG; Huang ZH
    World J Gastroenterol; 2016 Jul; 22(27):6235-45. PubMed ID: 27468213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lower expression of activating transcription factors 3 and 4 correlates with shorter progression-free survival in multiple myeloma patients receiving bortezomib plus dexamethasone therapy.
    Narita T; Ri M; Masaki A; Mori F; Ito A; Kusumoto S; Ishida T; Komatsu H; Iida S
    Blood Cancer J; 2015 Dec; 5(12):e373. PubMed ID: 26636288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intercellular transmission of the unfolded protein response promotes survival and drug resistance in cancer cells.
    Rodvold JJ; Chiu KT; Hiramatsu N; Nussbacher JK; Galimberti V; Mahadevan NR; Willert K; Lin JH; Zanetti M
    Sci Signal; 2017 Jun; 10(482):. PubMed ID: 28588081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
    Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
    Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib and endocannabinoid/endovanilloid system: a synergism in osteosarcoma.
    Punzo F; Tortora C; Di Pinto D; Pota E; Argenziano M; Di Paola A; Casale F; Rossi F
    Pharmacol Res; 2018 Nov; 137():25-33. PubMed ID: 30267762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.